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Background: Among Coronavirus Disease 2019 (COVID-19) manifestations, Olfactory (OD) and Gustatory (GD)
Dysfunctions (OGD) have drawn considerable attention, becoming a sort of hallmark of the disease. Many have
speculated on the pathogenesis and clinical characteristics of these disturbances; however, no definite answers
have been produced on the topic. With this systematic review, we aimed to collect all the available evidence
regarding the prevalence of OGD, the timing of their onset and their resolution, their rate of recovery and their
role as diagnostic and prognostic tools for Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)
infection.
Methods: A systematic review comprising all the observational studies that reported the prevalence and/or the
longitudinal trajectories of OGD in COVID-19 patients, as self-reported by patients or measured through objective
psychophysical tests.
Results: After the selection process, 155 studies were included, with a total of 70,920 patients and 105,291 not-
infected individuals. Prevalence reports were extremely variable across studies, with wide ranges for OD (0%–
98%) and GD (0–89%) prevalence. OGD occurred early during the disease course and only rarely preceded other
symptoms; out of 30 studies with a follow-up time of at least 20 days, only in 5 studies OGD fully resolved in more
than 90% of patients. OGD had low sensitivity and high specificity for SARS-CoV-2 infection; accuracy of OD and
GD for infection identification was higher than 80% in 10 out of 33 studies and in 8 out of 22 studies considered,
respectively. 28 out of 30 studies that studied the association between OGD and disease severity found how OGD
were associated with lower rates of severe pneumonia, hospitalization and mortality.
Conclusions: OGD seem to be highly prevalent in SARS-CoV-2 infection. They occur early, concomitantly with
other symptoms and often persist after recovery, in some cases for months; whether a full recovery eventually
occurs in all cases is not clear yet. OGD are good predictors of SARS-CoV-2 infection and are associated with a
milder disease course.1. Introduction
Coronavirus disease 2019 (COVID-19) is an infectious disease causedent of Neurosciences and Ment
rambilla).
6 May 2021; Accepted 9 May 2
evier Inc. This is an open access aby the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2); it
has been declared a pandemic on March 11, 2020 by the World Health
Organization (WHO, 2020). As of January 2021, more than 80 millional Health, Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, via F.
021
rticle under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
A. Boscutti et al. Brain, Behavior, & Immunity - Health 15 (2021) 100268cases have been reported worldwide, causing over 1,800,000 deaths
(John Hopkins Coronavirus Resource Center) as well as significant social
and economic suffering.
While approximately half of those infected experience an asymp-
tomatic disease course, the most common clinical manifestations are, in
descending order of frequency, fever, cough, headache and sore throat
(Lavezzo, 2020). Some patients, typically those of older age and/or
suffering from other coexisting clinical conditions, may develop more
severe forms of the disease, characterized by worsening of the respiratory
dysfunction, acute respiratory distress syndrome, septic shock and,
potentially, multi-organ failure (Wu et al., 2020).
In addition to the clinical scenario described above, a variety of other
“non-typical” manifestations have been described in patients with
COVID-19, including neurological (Mao et al., 2020a), psychiatric and
neuropsychiatric (Rogers et al., 2020), cardiovascular (Zheng et al.,
2020a), gastrointestinal (Jin et al., 2020), dermatological (Recalcati,
2020) and pediatric (Cruz and Zeichner, 2020) manifestations, which
have been postulated to be the result of the trophism of human respira-
tory coronaviruses for multiple human tissues (Gupta et al., 2020;
Schurink et al., 2020).
Among the extrapulmonary manifestations, the perceived high
prevalence of olfactory and gustatory dysfunctions (OGD) had great
resonance, even in the non-scientific community (Rabin, 2020; Asimov,
2020), eventually becoming a sort of “hallmark” of the disease. Conse-
quently, the presence of OGD in COVID-19 patients has been consistently
reported by authors from the early phases of the pandemic.
While a considerable amount of systematic reviews and meta-
analyses have already been published on the topic (n ¼ 15) (Hannum
et al., 2020; Saniaslaya et al., 2020; Pang et al., 2020; Hajikhani et al.,
2020; Ibekwe et al., 2020; Giorli et al., 2020; Von Bartheld et al., 2020a;
Chi et al., 2020; Agyeman et al., 2020; Desiato et al., 2020; Rocke et al.,
2020; Borsetto et al., 2020; Suratannon et al., 2020; Aziz et al., 2020;
Tong et al., 2020), there are several reasons why we feel that our review
can add valuable results for the readers.
First, the most updated database search was August 15th (Von Bar-
theld et al., 2020a); given the high rate of publication on COVID-19
(Putman et al., 2020), we expected that a high number of studies
would have been published in the following months. Second, while all
the meta-analyses cited above reported the prevalence of OGD, only few
explored other aspects of these manifestations. In particular, only one
meta-analysis collected data regarding the average duration of OGD (Von
Bartheld et al., 2020a) (updated until August 15th - 104 studies
included), and only one meta-analysis reported the timing of onset of
OGD relative to other COVID-19 symptoms (Chi et al., 2020) (updated
until May 8th – 12 studies included); no meta-analysis mentioned if any
information on longitudinal trajectories of OGD symptoms was present in
the studies included. Regarding the usefulness of OGD as predictors of
SARS-CoV-2 infection, only one meta-analysis focused on this aspect,
reporting the pooled positive predictive value of OGD in relation to
SARS-CoV-2 positivity (Rocke et al., 2020) (updated until April 18th - 12
studies included). Finally, only one study collected data for the estima-
tion of the relationship between the presence of OGD and the severity of
the disease, expressed as the need for hospitalization (Giorli et al., 2020)
(updated until June 1st – 11 studies included).
In this context, we performed a systematic review of studies focusing
on OGD in COVID-19 in order to address the following points:
a) Define OGD prevalence in COVID-19 patients and, if present, in a
control group of healthy patients or patients with other upper-
respiratory conditions.
b) Define the timing of OGD occurrence, and in particular the timing of
onset relative to COVID-19 “typical” symptoms.
c) Define the longitudinal trajectories of OGD in terms of recovery or
persistence.
d) Define the potential role of OGD as a diagnostic and predictive tool
for SARS-CoV-2 infection.2
e) Define the potential role of OGD as a predictor of severity and prog-
nosis of COVID-19.
2. Methods
We structured our systematic review on the basis of the Conducting
Systematic Reviews and Meta-Analyses of Observational Studies of Eti-
ology (COSMOS-E) guidelines (Dekkers et al., 2019). The Preferred
Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA)
tool (Liberati et al., 2009) was adopted for reporting.
2.1. Eligibility criteria
The study design of each report was evaluated following the
STrengthening the Reporting of OBservational studies in Epidemiology
(STROBE) guidelines (von Elm et al., 2007). The following design were
included: cohort (with or without a control group), case-control and
cross-sectional studies. Case series were excluded unless they provided
follow-up data regarding OGD. Case reports or studies with sample <10
were not considered for inclusion.
No restrictions were posed regarding the definition of the population
of interest, except for the presence of any medical condition associated
with OGD (e.g., Parkinson disease).
The only criterion for inclusion was SARS-CoV-2 positivity, defined as
SARS-CoV-2 genome detection by real-time reverse transcription poly-
merase chain reaction (RT-PCR) or antigen detection on nasal, pharyn-
geal or respiratory sample. We also included studies that defined
exposure as positivity to serological testing (irrespective of the assay
employed) (Houlihan and Beale, 2020).
Absence of exposure was defined as a negative result on the SARS-
CoV-2 testing methods mentioned above. The presence of an unex-
posed control group was not necessary for a study to be included.
The outcome of interest was the occurrence of olfactory or gustatory
disturbances. We did not pose limits regarding the way by which OGD
were defined, and we included studies that assessed OGD through review
of medical records, face to face or telephone clinical interviews, admin-
istration of web- or mobile application-based questionnaires. We also
included studies that employed objective testing to assess OGD; no lim-
itations were put regarding the type of psychophysical test adopted.
2.2. Search strategy
To identify potentially relevant records, PubMed, EMBASE and Web
of Science databases were searched from December 1st, 2019 to October
8th, 2020. Only studies in English were considered. The search was rerun
weekly, and last updated on December 14th.
The following string was used in PubMed and adapted for the other
two databases:
"(coronavirus OR sars OR covid) AND (smell OR taste OR olfactory OR
gustatory OR odor OR flavor OR anosmia OR hyposmia OR dysosmia OR
ageusia OR hypogeusia OR dysgeusia OR chemosensory)."
2.3. Study selection process
Search results were exported into reference manager software Sys-
tematic Review Accelerator © and EPPI-Reviewer 4 © for duplication
removal. Rayyan QCRI © was used for the screening process.
All the records were screened by title and abstract by two indepen-
dent authors (AB and GD); on the second level of screening, full text of
publications was evaluated by AB and VC; disagreements on study se-
lection were resolved by consensus with the involvement of a third
author (AP).
2.4. Data extraction
A preliminary data extraction form was designed by AB; it was then
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With the search being rerun on a weekly basis, data from newly included
study were updated accordingly.
The following variables were extracted from each study included:
1) Bibliographic information, study design
2) Population and control: number of participants, nationality, type of
control group (healthy vs other upper-respiratory viral disease)
3) Exposure: SARS-CoV-2 diagnosis modality, disease severity (outpa-
tient management vs hospitalization)
4) Outcome: OGD assessment modality (subjective and objective),
prevalence, timing of onset, longitudinal trajectories
5) Measures of effect: unadjusted and adjusted Odds Ratio (OR) and
Relative Risk (RR) for the association between OGD and SARS-CoV-2
infection and COVID-19 severity. Sensitivity (Sn), Specificity (Sp),
Positive Predictive Value (PPV), Negative Predictive Value (NPV),
Positive Likelihood Ratio (PLR) and Negative Likelihood Ratio (NLR)
of OGD for SARS-CoV-2 infection and COVID-19 severity. If not re-
ported by authors of the original study, Sn, Sp, PLR and NLR were
calculated from studies that provided data about OGD in both SARS-
CoV-2 positive individuals and negative controls.Fig. 1. Flow-chart summary of the study selection process (a
3
2.5. Risk of bias assessment
To assess the risk of bias of the studies included, a modified version of
the Newcastle-Ottawa Scale was used. The original version of the in-
strument was adapted for the cross-sectional, cohort and case-control
studies included; the three adaptations are made available in the Sup-
plementary Material. A particular focus was put on the representativeness
of the sample (i.e., selected on the basis on hospital admission vs general
population screening processes), on the ascertainment of the exposure
(RT-PCR vs serology) and on the assessment of outcome (i.e., psycho-
physical testing or validated questionnaires vs anamnestic or chart-
based). The maximum score attainable for a study was 9. For the risk
of bias evaluation, the following categorization was considered: 0–3 Very
High Risk, 4–6 High Risk, 7–9 Low Risk.
3. Results
3.1. Study selection
After the selection process, a total of 155 records met the inclusion
criteria. A total of 3394 papers were retrieved from databases; afterdapted from PRISMA guidelines (Liberati et al., 2009)).
Table 1
Table summary of the main characteristics of the included studies.






















































































































A. Boscutti et al. Brain, Behavior, & Immunity - Health 15 (2021) 100268duplication removal, 1667 records remained and were screened through
title and abstract. 306 articles were considered for full text examination,
and 152 were excluded (Fig. 1).3.2. Study characteristics
The studies characteristics and main findings are summarized below
and in Table 1; a detailed report of all the records included is provided in
a table format and can be found in the supplementary material section
(Supplementary Material - Table 1).
When the study design was mislabeled by authors, the design re-
ported was ignored and we labeled the study following the STROBE
guidelines (von Elm et al., 2007). In this way, 91 (59%) studies were
classified as cross-sectional, and 64 (41%) studies were labeled as cohort
studies. Only one study had a case-control design (Joffily et al., 2020).
Since a meta-analysis outlined how OGD prevalence is significantly
higher in Caucasians compared to Asian individuals (Von Bartheld et al.,
2020b), we included the nationality of the population of the study among
the variables collected. In our review, most studies (n ¼ 112) were4
performed in Europe or North America (n ¼ 41,998 individuals), with
only 13 records (n ¼ 6671) collecting data on Asian populations.
A total of 58,854 patients were included; 53,196 were confirmed by
RT-PCR (n ¼ 136 studies), while 5516 were defined by antibody detec-
tion (n ¼ 17 studies); in two records, both techniques were used (Le Bon
et al., 2020a; Merkely, 2020). Given the heterogeneity in the way the
studies reported disease severity, when possible, we tried to dichotomize
disease severity as the need for hospitalization; otherwise, we labeled
disease severity as reported by authors. Disease severity was character-
ized by 87 papers; 6036 individuals were managed as outpatients and/or
were classified as having an asymptomatic or mild form of the disease (n
¼ 20 studies); 6207 were hospitalized and/or were classified as having a
moderate to severe disease course (n¼ 37 studies). Other studies (n¼ 30,
n ¼ 53,196 individuals) considered a variably wide range of disease
severity (from asymptomatic to severe, from outpatient course to ICU
stay).
A total of 105,291 healthy controls (defined either with RT-PCR or
serology) were included (n ¼ 57 studies).
3.3. Subjective OGD assessment tools
A subjective report of OGD presence was collected by most studies (n
¼ 145 for OD, n ¼ 131 for GD); in most cases, clinical information was
gathered through retrospective review of medical records, face to face or
telephone clinical interviews, administration of web- or mobile
application-based questionnaires. However, in a minority of studies OGD
presence was assessed through validated questionnaires (n ¼ 15). The
Sino-Nasal Outcome Test (SNOT-22) (Hopkins et al., 2009) contains 22
items which evaluates ear-nose-throat symptoms and their impact on
quality of life; item 5, which enquires OGD, was used by 4 studies
(Mercante et al., 2020), (Ramasamy et al., 2020), (Cocco et al., 2020),
(Boscolo-Rizzo et al., 2020). The National Health and Nutrition Exami-
nation Survey (NHANES) (Hoffman et al., 2016) contains 8 items which
explore subjective and objective OGD; the subjective part was used by 3
records (Lechien et al., 2020a), (Lechien et al., 2020b), (Fantozzi et al.,
2020). The Global Consortium for Chemosensory Research (GCCR) offers
an online survey (GLOBAL CONSORTIUM FOR CHEMOSENSORY
RESEARCH) that employs both binary response and visual analog scales
to measure subjective OGD; it was employed by 2 studies (Gerkin et al.,
2020), (Parma et al., 2020a). Finally, the American Academy of
Otolaryngology-Head and Neck Surgery (AAO-HNS) COVID-19 Anosmia
Reporting Tool was designed for healthcare providers, and it can be used
to submit anonymous information about OGD in COVID-19 patients
(COVID-19 Anosmia Reporting Tool); it was employed by 2 studies
(Sayin, 2020), (€Ozçelik Korkmaz et al., 2020).
3.4. Objective OD assessment tools
OD was evaluated through psychophysical testing in 21 studies. The
Sniffin’Sticks' test was themost commonly employed objective test (n¼ 8
studies) (Sanli et al., 2021), (Lechien et al., 2020c), (Le Bon et al., 2020b),
(Otte et al., 2020), (Altin et al., 2020), (Lechien et al., 2020a), (Iannuzzi
et al., 2020), (G€ozen et al., 2020). Through pen-like odor dispensing
devices, it assesses three olfactory functions, i.e. odor threshold, odor
discrimination and odor identification (Hummel et al., 1997). The Con-
necticut Chemosensory Clinical Research Center Test (CCCRC) was
employed by 4 studies (Vaira et al., 2020a), (Vaira et al., 2020b), (Vaira
et al., 2020c); it consists of a threshold test employing 1-buthanol as the
odorant, and an odor identification test with natural items (Cain et al.,
1988). The University of Pennsylvania Smell Identification Test (UPSIT)
was employed by 3 studies (Moein et al., 2020a, 2020b), (Lima et al.,
2020); it utilizes microcapsulated crystals for odor presentation and
identification (Doty et al., 1984). Notably, UPSIT and CCCRC has been
proved to be highly correlated in their scoring (Cain and Rabin, 1989).
Finally, 2 studies (Bhattacharjee et al., 2020), (Li et al., 2020a) used
olfactometric techniques; while Li et al. used the Toyota-Takagi (T&T)
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ten-channel olfactometer for olfactory detection and matching.
3.5. Objective GD assessment tools
Psychophysical validated evaluation of GD was performed in only 8
records (Vaira et al., 2020d), (Vaira et al., 2020c), (Vaira et al., 2020b),
(Vaira et al., 2020a), (Petrocelli et al., 2020), (Hintschich et al., 2020), (Le
Bon et al., 2020a), (Altin et al., 2020). In 4 of them (Vaira et al., 2020d),
(Vaira et al., 2020c), (Vaira et al., 2020b), (Vaira et al., 2020a), (Petrocelli
et al., 2020), a four-item (sweet, salty, sour, bitter) test (Massarelli et al.,
2018) was administrated, both in sample of hospitalized patients and a
sample of outpatients (self-administered) (Vaira et al., 2020e). “Taste
strips”, spoon-shaped filter paper strips impregnated with the four taste
qualities (Landis et al., 2009) were used in 2 records (Hintschich et al.,
2020), (Le Bon et al., 2020a).
3.6. Prevalence of OGD
Aggregated prevalence (presence of either OD or GD) was given in 56
studies (36%), with a large inter-study variability (range: 1.5% (Pinato
et al., 2020) – 91% (Otte et al., 2020)).
Prevalence of OD was reported by 95 studies (62%), with extreme
variability between studies (range: 0% (Hauchecorne et al., 2020) – 98%
(Moein et al., 2020c)).
Prevalence of GD was reported by 92 studies (59%); the large inter-
study variability was confirmed also for this disturbance (range: 0%
(Hauchecorne et al., 2020) – 89% (Paderno et al., 2020)).
Considering only studies that performed psychophysical testing for
OD (n ¼ 21), the lowest prevalence reported for OD was 19% (Romer-
o-Gameros et al., 2020). In studies reporting both subjective and objec-
tive evaluations, those appeared to differ. In some cases, objective
evaluation was more sensible to detect OD in those denying such dis-
turbances (Lima et al., 2020), (G€ozen et al., 2020). However, quite sur-
prisingly, the opposite held true in some other cases, with subjective
reports showing larger prevalence of OD compared to psychophysical
testing (Romero-Gameros et al., 2020), (Hintschich et al., 2020), (Lechien
et al., 2020a); nonetheless, in Lechien et al. (2020a) objective evaluation
was performed only in a small subset of the total sample (93 out of 2013
patients).
Considering only studies that performed psychophysical testing for
GD (n ¼ 21), lowest prevalence reported was 20% (Hintschich et al.,
2020); in this study, similarly to what reported above for OD, the authors
found GD prevalence to be lower when assessed by psychophysical
testing compared to subjective reporting (Hintschich et al., 2020).
When comparing prevalence based on SARS-CoV-2 testing, lowest
prevalence among studies for OD and GD were 21% (Foster et al., 2020)
and 33% (Nouchi et al., 2020), respectively, when considering only
SARS-CoV-2 diagnosis through serology (n ¼ 17, 11%). When restricting
results to cross-sectional studies, lowest prevalence reported for OD and
GD were 5% (Romero-Sanchez et al., 2020), (Mao et al., 2020b) and 6%
(Romero-Sanchez et al., 2020), (Mao et al., 2020b), respectively.
Finally, we grouped studies based on nationality of the population,
with one group comprising studies carried out in the European Union or
United States (n ¼ 111, 71%), and the other including investigations
performed in the rest of the world (n¼ 45, 29%). In the European Union/
United States group, prevalence range for OD and GD were 0% (Hau-
checorne et al., 2020) - 98% (Moein et al., 2020c) and 080–89% (Paderno
et al., 2020), respectively; in the rest of the world group, prevalence
range for OD and GD were 1% (Chachkhiani et al., 2020) - 89% (Al-Zaidi
and Badr, 2020) and 1 (Chachkhiani et al., 2020) - 87% (Venugopal et al.,
2021), respectively.
3.7. OGD onset timing
Data regarding onset of OGD was given by 43 studies (28%). Nearly5
all the reviewed studies agree in showing that OGD occur early during
the course of the disease, being among the first symptoms noted by pa-
tients; only 3 papers reported a late presentation of these disturbance,
which appeared after all other symptoms in more than 50% of patients
(Lechien et al., 2020d), (Lechien et al., 2020a), (Samimi Ardestani et al.,
2020). Most of the times OGD occurred concurrently to other COVID-19
symptoms; only in 2 studies OGD preceded other disturbances in more
than 50% of patients (Lima et al., 2020), (Gelardi et al., 2020).
3.8. OGD longitudinal course and recovery rate
58 (37%) of studies focused on the longitudinal course and recovery
rate of OGD. Across all studies, OGD was generally persistent, and a
significant number of patients recovered only partially during the first
weeks after resolution of other symptoms.
In particular, 30 (19%) studies obtained follow-up data (either with a
prospective or retrospective approach) for at least 20 days after OGD
onset; only in 5 OGD persisted in less than 10% of patients that originally
developed these symptoms (Lv et al., 2020), (Boscolo-Rizzo et al., 2020),
(Baron-Sanchez et al., 2020), (Mishra et al., 2020), (Komagamine and
Yabuki, 2020). Of note, among the four studies with the longest
follow-up time (i.e. 57.94 1.40 (Otte et al., 2020), 62 (range 25–95) (Li
et al., 2020a), 117 (range 41–193) (Stavem et al., 2020) and 125
(45–215) (Petersen et al., 2020) days after symptom onset) recovery rates
were 54%, 89%, 88% and 84%, respectively.
In those who recovered, most studies reported that OGD resolved
within 2 weeks after onset. In fact, mean or median duration of OGD was
more than 14 days in only 3 studies (Sheng et al., 2020), (Garg et al.,
2020), (Meini et al., 2020).
3.9. OGD association with SARS-CoV-2 infection risk
Of the 59 studies that enrolled a control group of healthy individuals,
51 studies reported results of statistical test run to evaluate the associa-
tion between presence of OGD and SARS-CoV-2 infection risk. In all
studies, OGD were significantly more prevalent in patients positive to
SARS-CoV-2 via RT-PCR or serology (COVIDþ). 12 studies performed
regression analyses adjusted for demographic and clinical variables. OGD
were found to be associated with COVID þ after adjustment for de-
mographic (Waterfield et al., 2020), (Adorni et al., 2020), (Tudrej et al.,
2020), (Venugopal et al., 2021), (Just et al., 2020), (Menni et al., 2020),
(Lee et al., 2020), (Ganz-Lord et al., 2020), (Bidkar et al., 2020), clinical
(Waterfield et al., 2020), (Adorni et al., 2020), (Tudrej et al., 2020),
(Venugopal et al., 2021), (Just et al., 2020), (Lee et al., 2020), (Ganz-Lord
et al., 2020) and laboratoristic (Tudrej et al., 2020) variables.
Sn, Sp, PLR and NLR were calculated for 51 studies; data are sum-
marized as their range in Table 2, while the values for each study are
reported in Supplementary Tables 3–5. In general, OGD had low sensi-
tivity and high specificity for the diagnosis of SARS-CoV-2. Overall, ac-
curacy of OGD (presence of OD or GD) for SARS-CoV-2 diagnosis was
higher than 80% in 13 out of 22 studies, accuracy of OD was higher than
80% in 10 out of 33 studies; finally, accuracy of GD for diagnosis was
higher than 80% in 8 out of 22 studies.
3.10. OGD association with COVID-19 severity
A total of 30 studies examined the relationship between OGD and
severity of COVID-19; 12 did not find any significant association between
the two variables (Moein et al., 2020c), (Petrocelli et al., 2020), (Lee
et al., 2020; €Ozçelik Korkmaz et al., 2020; Ninchritz-Becerra et al., 2020;
Romero-Gameros et al., 2020; Cocco et al., 2020; Mao et al., 2020b;
Petersen et al., 2020; Al-Zaidi and Badr, 2020; Makda et al., 2020;
Izquierdo-Domínguez et al., 2020).
In the others, the presence of OD was associated with a milder clinical
course, and in particular with decreased risk of developing pneumonia
(Klopfenstein et al., 2020), (Castelli et al., 2020), (Romero-Sanchez et al.,
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et al., 2021), decreased need for hospitalization (Salepci et al., 2020;
Foster et al., 2020; Izquierdo-Domínguez et al., 2020; Paderno et al.,
2020; Yan et al., 2020a; Nouchi et al., 2020; Avcl et al., 2020; Klopfen-
stein et al., 2020; D'Ascanio et al., 2020; Siso-Almirall et al., 2020),
decreased need for oxygen therapy (Klopfenstein et al., 2020), (Sayin,
2020), decrease need for Intensive Care Unit (ICU) admission
(Siso-Almirall et al., 2020), decrease Acute respiratory Distress Syndrome
(ARDS) rates (Foster et al., 2020), decrease need for intubation (Foster
et al., 2020), reduced mortality (Siso-Almirall et al., 2020).
In two records, the presence of persistent OD was associated with
increased need for hospitalization (Vaira et al., 2020b), (Vaira et al.,
2020c); conversely, another study found that the frequency of smell
function recovery was lower among non-hospitalized patients (Foster
et al., 2020).
Presence of GD was associated with decreased risk of developing
pneumonia ((Romero-Sanchez et al., 2020)) and decrease need for hos-
pitalization (Paderno et al., 2020), (Yan et al., 2020b), (Nouchi et al.,
2020), (Siso-Almirall et al., 2020).
Finally, regarding aggregate OGD prevalence, in a study involving
12,066 patients, ascendant hierarchical clustering was applied to
generate four phenotypic clusters, one of which included OD and GD.
This cluster was the one associated with the lowest rate of ICU admission
and mortality (Rubio-Rivas et al., 2020). Similarly, in another record
OGD was associated with lower rates of hospitalization and ICU admis-
sion (Chary et al., 2020).
3.11. Risk of bias
Overall, quality of evidence was low for most of the studies included.
11 studies were considered to have a very high risk of bias (n ¼ 2104
individuals), 118 records were classified as having a high risk of bias (n
¼ 47,523 individuals), while only 26 reports were labeled as low risk of
bias (n ¼ 9227 individuals).
4. Discussion
The large number of studies included in this review reflects the
magnitude of interest that the topic of chemosensory disturbances has
attracted among the scientific community. In this review, we focused
solely on clinical studies on OGD in SARS-CoV-2 infection; however,
numerous other records have also provided some insights on the etio-
pathological basis of SARS-CoV-2-related OGD, from pre-clinical studies
in animal models, to post-mortem histological analyses and neuro-
imaging findings. A summary of these studies can be found in Box 1.
The main findings of our systematic review can be summarized as
following: a) The prevalence of OGD was significant in patients with
SARS-CoV-2 infection, with a large variability across studies and a wide
range of prevalence estimates, b) OGD appeared early during the disease
and, most of the time, concurrently with other COVID-19 typical symp-
toms, c) In those who fully recover, OGD were generally short-lived, with
most of the cases resolving within 14 days. However, in a non-negligible
proportion of patients, OGD recovery was partial or absent even after
months of follow-up, d) OGD presence was a reliable diagnostic tool for
SARS-CoV-2, especially in ruling in SARS-CoV-2 diagnosis, e) OGD were
associated with a milder course of disease, a decreased need for hospi-
talization and lower mortality rates.
4.1. OGD prevalence in SARS-CoV-2 infection
A key point that influences the results of prevalence studies is how
outcomes are defined (Radke et al., 2019). In the case of OGD, outcome
could be defined as ascertained by subjective testing (clinical interviews,
administration of questionnaires, retrospective medical chart screening)
or objective testing, carried through psychophysical tests. Intuitively, it
could be expected that psychophysical testing is more sensitive in6
detecting chemosensory dysfunction. However, from the reviewed
studies it emerged that psychophysical testing was not always the most
sensitive measure, since in some records (Romero-Gameros et al., 2020),
(Hintschich et al., 2020), (Lechien et al., 2020a) the prevalence of
self-reported OGD was higher than the one derived from objective
testing; in other cases, the opposite was true (Lima et al., 2020), (G€ozen
et al., 2020), with psychophysical testing reporting higher prevalence.
Reports showed how absence of self-reported GD has high negative
predictive value regarding the presence of GD as determined by objective
testing (Soter et al., 2008); in this sense, since high negative predictive
value is associated with high sensitivity, this finding suggests how based
self-reported OGD could be at least as reliable as objective methods. In
fact, self-reported OD severity has been found to correlate fairly well with
psychophysical testing OD scores (Seok et al., 2017).
All the studies that employed objective testing used validated psy-
chophysical tests, whose scores could be therefore expected to be highly
reliable when compared with each other. However, Marino-Sanchez
et al. (Mari~no-Sanchez et al., 2020) raised an important point
regarding the replicability of tests across different countries. As an
example, they refer to the study by Moein et al. (2020c) which found, in
an Iranian sample of COVID-19 patients, a prevalence of 98% for OD
when measured by UPSIT. Marino-Sanchez et al. suggest how this
extremely high prevalence could be influenced by the fact that UPSIT is
only validated and commonly used in the US. The validity of this
observation seems to be supported by the fact that Moein et al. found a
very high prevalence of OD in the healthy controls sample, probably
since the UPSIT olfactory stimuli, familiar to the US population, were not
recognized by the Iranian sample. The fact that the reliability of OGD
testing is highly dependent on whether the test is validated in the country
of interest is probably an understated problem across studies on OGD
prevalence in SARS-CoV-2 infection, since this potential issue was not
addressed in any of the papers included in this review.
Furthermore, it must be noted that OGD are significantly prevalent in
the general population, with recent estimates pointing at an OD preva-
lence of 22% (Desiato et al., 2020) and a GD prevalence of 17% (Liu et al.,
2016). Nonetheless, 31% of the studies considered in this review
included a control group of SARS-CoV-2 negative patients and run a
statistic test to determine whether OGD scores were significantly
different in the two groups; in all studies, OGD were more prevalent in
the group of SARS-CoV-2 positive individuals.
4.2. OGD timing of onset and longitudinal trajectories
Early anecdotal reports suggested how OGD could represent the first
symptom of SARS-CoV-2 infection in the majority of cases (€Ozçelik
Korkmaz et al., 2020). While the reviewed studies confirmed that OGD
occur early in the disease course, OGD preceded other COVID-19
symptoms only in a minority of cases.
On the other hand, the notion of high rates of persistence of OGD after
the resolution of other COVID-19 symptoms was confirmed by several
follow-up studies. The study reporting the longest follow-up time was
that by Petersen et al. (2020)., which reported, after a mean of 125 days
after OGD onset, the presence of residual OD and GD in 24% and 16% of
patients, respectively. At present, whether SARS-CoV-2-related OGD are
completely reversible remains an open question; since chronic OGD is
associated with disturbances in eating behavior, depression and a general
reduction of the quality of life (Croy et al., 2014; Baharvand et al., 2013),
future studies following-up patients with residual OGD and reporting
their outcomes are warranted.
4.3. OGD as a diagnostic marker for SARS-CoV-2 infection
In about one third of the included studies, a group of both SARS-CoV-
2 negative (COVID-) and SARS-CoV-2 positive (COVID-þ) were included,
thus allowing to test the efficacy of OGD as a diagnostic marker for the
infection (Table 2, Supplementary Tables 3–5).
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infection, even more so considering that these were symptoms often self-
referred by patients; as a benchmark, clinical symptoms used to diagnose
community acquired pneumonia all seem to perform worse than OGD for
the diagnosis of SARS-CoV-2 infection (Ebell et al., 2020). Moreover,
high specificity and low sensibility values were found consistently across
studies, ultimately suggesting that while the absence of OGD is not usefulBox 1
UNCOVERING THE ETIOPATHOLOGICAL ROOTS OF SARS-CoV-2 RELATED OLFACTOR
IMAGING FINDINGS
The etiology of OD dysfunctions in the SARS-CoV-2 infection has been the subject of discuss
relevant findings on the topic coming from preclinical, histopathological (biopsies, post-m
Of note, we did not find any original study regarding the etiopathogenesis of gustatory dysfun
OD.
Preclinical studies
Many have suggested that the high rates of neurological complications seen in COVID-19 (Fav
potential (Orrù et al., 2020).
All the preclinical studies conducted on murine models agree on the fact that the major target
sustentacular cells (Bryche et al., 2020; DeMelo et al., 2020; Zhang et al., 2020; Rodriguez e
olfactory sensory neurons in their functions (Vogalis et al., 2005). Sustentacular cells expre
Transmembrane Serine Protease 2 (TMPRSS2) (Sun et al., 2020), (Chen et al., 2020); inte
(Bilinska et al., 2020). When the virus gets inoculated in murine models, it could be found i
Zhang et al., 2020; Zheng et al., 2020b) causing severe and acute olfactory dysfunction. S
suggested that the olfactory dysfunction is mainly caused by down-expression of olfactory
activation of the innate immune response (Rodriguez et al., 2020).
Whether SARS-CoV-2 infects the neuronal cells of the olfactory systems remains unclear. Wh
particles in olfactory sensory neurons, olfactory bulb, olfactory tracts and olfactory cortex
records reported the presence of the virus in the olfactory sensory neurons (De Melo et al.,
olfactory bulb (De Melo et al., 2020). Interestingly, since SARS-CoV-2 cellular entry protei
cells, with another study showing infection of the immature olfactory sensory neurons (Zha
through infection of its immature cells.
Histopathological studies on humans
Evidence from histopathological findings on human tissues suggest a neuroinvasive potential
and the olfactory pathway.
Specifically, biopsies taken from patients with COVID-19 related olfactory dysfunction showe
epithelium, with a clear inflammatory signature demonstrated by increased levels of tumor
et al., 2020f). Of note, histological alterations can still be found several weeks after the ac
(Vaira et al., 2020f) and 6 (De Melo et al., 2020) months after initial diagnosis showing e
particles.
Results from post-mortem histological analyses confirmed the presence of SARS-CoV-2 in th
olfactory nerve (Bulfamante et al., 2020) and inflammatory neuropathy of the olfactory trac
pathway such as the olfactory bulb was also reported, with presence of viral genetic mate
inflammatory activity (Morbini et al., 2020) and high degree of astrogliosis and microglio
Neuroimaging findings in OGD
Scoping the literature, we retrieved 20 records in which COVID-19 with OGD were studied w
Tomography (PET) and Magnetic Resonance Imaging (MRI).
Specifically, the olfactory cleft anatomy was studied by 3 records, which reported thickening a
probably caused by mucosal edema as suggested by MRI T2 hyperintensity (Altundag et a
patients, since the olfactory cleft represents the entry route of odorant molecules to the olfa
olfactory areas (Naeini et al., 2020).
9 MRI studies reported relevant findings regarding olfactory bulb structure in anosmic COV
Olfactory bulb dimensions were often found to be altered. A case report reported an enlarg
(Laurendon et al., 2020); conversely, 5 studies reported a decrease in the size of the olfactor
Liang et al., 2020). Notably, out of these 5 studies, three (Kandemirli et al., 2020; Tsivgoulis
duration) anosmia. This finding seems to agree with the notion by which reduced dimensi
with longer duration of the chemosensory impairment (Eliezer et al., 2020), (Naeini et al
Alterations in signal intensity within the olfactory bulb were also commonly reported, with
FLAIR signal abnormalities (Strauss et al., 2020; Chetrit et al., 2020) and injury of the olfact
images (Arag~ao et al., 2020).
However, it must be outlined that olfactory bulbs hyperintensities in T2-FLAIR are a relative
control group is warranted for a correct interpretation of these findings. In addition, given
evaluations must be performed in order to avoid misinterpretation of paraphysiological fin
key target of SARS-CoV-2 infection and a possible neuroimaging marker of olfactory dysf
Involvement of the olfactory tracts was also reported, with evidence of bilateral T2 FLAIR an
2020), suggestive of olfactory tract inflammatory neuropathy.
Finally, reports of alterations in cortical regions involved in processing of olfactory inputs w
alterations of the right gyrus rectus were found in the form of FLAIR hyperintensity (Politi
brain PET imaging found rectal gyrus metabolism to be greatly reduced on the right side. M
of 5 out of 23 patients studied (Kandemirli et al., 2020).
7
in excluding the possibility of infection, their presence “rule-in” the
possibility of SARS-CoV-2 diagnosis, thus representing a strong indica-
tion for more definitive testing. In this context, a preprint published by
the Global Consortium for Chemosensory Research (GCCR) demon-
strated how a continuous rating of current olfactory ability on a 0 to 10
rating scale was the best predictor of SARS-CoV-2 infection in a sample of
4148 COVIDþ and 546 COVID-; ratings 2 were associated with OR 2,Y DYSFUNCTION: EVIDENCE FROM PRECLINICAL, HISTOPATHOLOGICAL AND
ion since the beginning of the pandemic; in this section we try to summarize the most
ortem findings) and radiological studies on the topic.
ctions in SARS-CoV-2 infection; therefore, all the evidence presented belowwill focus on
as et al., 2020), including OGD, could be the consequence of SARS-CoV-2 neuroinvasive
for SARS-CoV-2 infection is the olfactory non-neuronal epithelium, and specifically the
t al., 2020; Zheng et al., 2020b; Sun et al., 2020), a glial-like cell population that support
ss high levels of the virus entry proteins Angiotensin-Converting Enzyme 2 (ACE2) and
restingly, these two proteins do not seem to be expressed olfactory sensory neurons
n the olfactory epithelium as early as two days after administration (Bryche et al., 2020;
ince virus particles were found in only 1% of the olfactory epithelium, it has been
receptors as a consequence of inflammatory cytokines release triggered by a strong
ile several studies employing animal models did not find any evidence of SARS-CoV-2
(Bryche et al., 2020; Rodriguez et al., 2020; Zheng et al., 2020b; Sun et al., 2020), two
2020; Zhang et al., 2020), and one documented infection of the neurons comprising the
ns ACE2 and TMPRSS2 have been found to be significantly expressed in olfactory stem
ng et al., 2020), it may be suggested that the virus reaches the olfactory neuroepithelium
SARS-CoV-2, with significant microstructural modifications of the olfactory epithelium
d the presence of viral particles with concomitant histological alterations of the olfactory
-necrosis factor alpha and interleukin-6 (De Melo et al., 2020; Torabi et al., 2020; Vaira
ute phase, with biopsies taken from patients with persistent olfactory dysfunction at 3
vidence of massive olfactory epithelium destruction and persistence of SARS-CoV-2
e olfactory epithelium (Meinhardt et al., 2020), with evidence of severe damage of the
ts (Kirschenbaum et al., 2020). Moreover, involvement of higher regions of the olfactory
rial and viral particles (Meinhardt et al., 2020; Morbini et al., 2020) and evidence of
sis (Matschke et al., 2020).
ith various neuroimaging tools such as Computed Tomography (CT), Positron Emission
nd obstruction of the olfactory cleft at the CT (Spoldi et al., 2020; Altundag et al., 2020),
l., 2020); this could be seen as a potential explanation of olfactory dysfunction in these
ctory epithelium. Another study, however, reported no evidence of involvement of these
ID-19 patients.
ement along with an increase in T2 signal intensity, findings suggestive of edema
y bulb (Kandemirli et al., 2020; Chiu et al., 2020; Li et al., 2020b; Tsivgoulis et al., 2020;
et al., 2020; Liang et al., 2020) were performed in patients with persistent (>1month in
on of the olfactory bulb in patients with post-infectious olfactory disorder is associated
., 2020).
diffuse hyperintense foci resembling microhemorrhages (Kandemirli et al., 2020), T2
ory bulbs demonstrated by pre-contrast and post-contrast fat suppression T1W and STIR
common finding in healthy subjects (Shor et al., 2020); for this reason, inclusion of a
the small volumes of olfactory bulbs, high resolution sequences and objective intensity
dings. Still, the evidence seems to point out that the olfactory bodies might represent a
unctions in SARS-Cov-2 infection.
d fat suppression hyperintensities and DWI abnormalities (Li et al., 2020b; Casez et al.,
ere also found. Specifically, in two MRI studies on COVID-19 patients with anosmia,
et al., 2020) and hemorrhage (Thu et al., 2020). In addition, a study employing F-FDG
oreover, a study reported the presence of FLAIR hyperintensity in the entorhinal cortex
Table 2
Diagnostic performances of presence of olfactory or gustatory dysfunction for the detection of SARS-CoV-2 infection.
Dysfunction Prevalence Sensitivity Specificity Positive Likelihood ratio Negative Likelihood ratio Accuracy
OGD 1.5% (Pinato et al.,
2020) – 91% (Otte
et al., 2020)





et al., 2020) – 99.72
(Vena et al., 2020)
0.80 (Kempker et al., 2020)
– 23.31 (Vena et al., 2020)
0.40 (Dawson et al., 2020) –
1.02 (Kempker et al., 2020)
24.88 (Kempker et al., 2020)
– 96.92 (Merkely, 2020)
OD 0% (Hauchecorne




et al., 2020) –
99.47 (Tostmann
et al., 2020)
4.76 (Joffily et al.,
2020) – 98.89 (Dixon
et al., 2020)
1.04 (Joffily et al., 2020) –
27.00 (Tostmann et al.,
2020)
0.01 (Therchilsen et al.,
2020) – 0.95 (Tostmann
et al., 2020)
46.42 (Bidkar et al., 2020) –
98.42 (Tostmann et al.,
2020)
GD 0% (Hauchecorne




et al., 2020) –
99.38 (Joffily
et al., 2020)





et al., 2020) – 41.14 (Lee
et al., 2020)




et al., 2020) – 95.46 (Dixon
et al., 2020)
OGD: Either Olfactory or Gustatory Dysfunctions (not specified by the studies).
Sensitivity, Specificity and Accuracy data expressed as percentages (%).
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tion with an OR of 10 (Gerkin et al., 2020).
4.4. OGD are specific symptoms of SARS-CoV-2 infection
Several studies showed how OGD were associated with SARS-CoV-2
infection independently from demographic, clinical or laboratory vari-
ables, ultimately supporting the notion by which OGD are specific
symptoms of SARS-CoV-2 infection, and not the product of confounders.
One of the most discussed candidates in the list of the potential con-
founders was the presence of nasal obstruction. Regarding this last point,
several of the studies included found nasal blockage to have a significant
lower prevalence than OGD in SARS-CoV-2 patients. In particular, two
papers from the GCCR (Gerkin et al., 2020; Parma et al., 2020b) showed,
through a principal component analysis, how OGD and nasal obstruction
were mostly uncorrelated, and thus unlikely to demonstrate a causal
relationship with each other.
4.5. OGD as a prognostic maker for SARS-CoV-2 infection
Various studies reported how OGD presence was associated with a
generally milder disease characterized by a decreased need for hospi-
talization, lower rates of severe pneumonia or ARDS, decreased need for
oxygen, intubation, and lower mortality rates. Among the hypotheses
proposed, the most common was the one suggesting that a strong
immunological response in the lymphatic tissue of the nasal mucosa
might be associated with higher rates of OGD, but also with a more
effective immune response and thus with a lower incidence of compli-
cations (Yan et al., 2020c); this hypothesis, however, has never been
tested in pre-clinical or clinical settings to date and awaits confirmation.
5. Limitations
Although the screening process was performed in a rigorous way, the
rate of publications on the topic has been unprecedented; moreover, most
authors performing clinical studies on SARS-CoV-2 have included, since
the beginning of the pandemic, data about prevalence of OGD. Therefore,
we could not exclude that some records could have been missed in the
selection process.
Studies were highly heterogeneous in their design, with some being
performed in hospital wards, others in emergencies department and
others being cross-sectional studies on SARS-CoV-2 serology. However,
we provided information regarding study design adopted, SARS-CoV-2
testing methodic employed, and the severity of patients studied. In
several studies, assessment of OGD presence was carried out retrospec-
tively through phone interviews or the administration of questionnaires
weeks or month after the disease onset; in this case, the presence of recall
bias could not be ruled out.
Finally, some of the reviewed studies investigated the rates of OGD8
resolution/recovery following-up the patients. However, while some of
these studies clearly stated the attrition rate (number of lost at follow-
up), others did not, ultimately limiting the reliability of OGD recovery
rates reported.
6. Conclusions
From the reviewed studies it emerged how OGD are prevalent in
patients with SARS-CoV-2 infection and how they can provide valuable
information for early detection of the disease and for its prognostic
stratification. Worrisome rates of OGD persistence are observed in the
medium-term, and to date it is not clear whether these disturbances are
fully reversible. Quality of the gathered evidence was generally low, with
most of the studies having a high risk of bias. Therefore, further studies
are warranted on this topic, since OGD may represent one of the long-
term complications of the disease.Declaration of competing interest
None.
Appendix A. Supplementary data
Supplementary data to this article can be found online at https://do
i.org/10.1016/j.bbih.2021.100268.
Funding sources
This work has been supported by Fondazione Cariplo, grant n 2020-
1366 to PB, within the call to support research into treatment, diagnosis
and detection of COVID-19 in partnership with the Lombardy Region and
Fondazione Veronesi.
References
Adorni, F., et al., 2020. Self-reported symptoms of SARS-CoV-2 infection in a
nonhospitalized population in Italy: cross-sectional study of the EPICOVID19 web-
based survey. JMIR Publ. Health Surveill. 6, e21866.
Agyeman, A.A., Chin, K.L., Landersdorfer, C.B., Liew, D., Ofori-Asenso, R., 2020. Smell
and taste dysfunction in patients with COVID-19: a systematic review and meta-
analysis. Mayo Clin. Proc. 95, 1621–1631.
Al-Zaidi, H.M.H., Badr, H.M., 2020. Incidence and recovery of smell and taste dysfunction
in COVID-19 positive patients. Egypt. J. Otolaryngol. 36.
Altin, F., Cingi, C., Uzun, T., Bal, C., 2020. Olfactory and gustatory abnormalities in
COVID-19 cases. Eur. Arch. Oto-Rhino-Laryngol. 277, 2775–2781.
Altundag, A., et al., 2020. Olfactory Cleft Measurements and COVID-19–Related Anosmia.
Otolaryngology - Head and Neck Surgery, United States. https://doi.org/10.1177/
0194599820965920.
Arag~ao, M.F.V.V., Leal, M.C., Cartaxo Filho, O.Q., Fonseca, T.M., Valença, M.M., 2020.
Anosmia in COVID-19 associated with injury to the olfactory bulbs evident on MRI.
Am. J. Neuroradiol. 41, 1703–1706.
Asimov, E., 2020. Rediscovering Wine after Covid-19. New York Times.
A. Boscutti et al. Brain, Behavior, & Immunity - Health 15 (2021) 100268Avcl, H., Karabulut, B., Farasoglu, A., Boldaz, E., Evman, M., 2020. Relationship between
anosmia and hospitalisation in patients with coronavirus disease 2019: an
otolaryngological perspective. J. Laryngol. Otol. 134, 710–716.
Aziz, M., et al., 2020. Taste changes (dysgeusia) in COVID-19: a systematic review and
meta-analysis. Gastroenterology 159, 1132–1133.
Baharvand, M., Shoalehsaadi, N., Barakian, R., Jalali Moghaddam, E., 2013. Taste
alteration and impact on quality of life after head and neck radiotherapy. J. Oral
Pathol. Med. 42, 106–112.
Baron-Sanchez, J., Santiago, C., Goizueta-San Martín, G., Arca, R., Fernandez, R., 2020.
Smell and Taste Disorders in Spanish Patients with Mild COVID-19. Neurología,
English Edition. https://doi.org/10.1016/j.nrleng.2020.07.007.
Von Bartheld, C.S., Butowt, R., Hagen, M.M., 2020. Prevalence of chemosensory
dysfunction in COVID-19 patients: a systematic review and meta-analysis reveals
significant ethnic differences. ACS Chem. Neurosci. 11, 2944–2961.
Von Bartheld, C.S., Butowt, R., Hagen, M.M., 2020. Prevalence of chemosensory
dysfunction in COVID-19 patients: a systematic review and meta-analysis reveals
significant ethnic differences. ACS Chem. Neurosci. 11, 2944–2961.
Bhattacharjee, A.S., Joshi, S.V., Naik, S., Sangle, S., Abraham, N.M., 2020. Quantitative
assessment of olfactory dysfunction accurately detects asymptomatic COVID-19
carriers. SSRN Electron. J. https://doi.org/10.2139/ssrn.3622362.
Bidkar, V., et al., 2020. Testing olfactory and gustatory dysfunctions among quarantine
COVID-19 suspects. Indian J.Otolaryngol. Head Neck Surg. https://doi.org/10.1007/
s12070-020-02210-3.
Bilinska, K., Jakubowska, P., Von Bartheld, C.S., Butowt, R., 2020. Expression of the
SARS-CoV-2 entry proteins, ACE2 and TMPRSS2, in cells of the olfactory epithelium:
identification of cell types and trends with age. ACS Chem. Neurosci. 11, 1555–1562.
Lavezzo, E., et al., 2020. Suppression of a SARS-CoV-2 outbreak in the Italian
municipality of Vo ’. Nature 584 (7821), 425–429. https://doi.org/10.103
8/s41586-020-2488-1.
Le Bon, S.D., et al., 2020. Psychophysical Evaluation of Chemosensory Functions 5 Weeks
after Olfactory Loss Due to COVID-19: a Prospective Cohort Study on 72 Patients.
European Archives of Oto-Rhino-Laryngology. https://doi.org/10.1007/s00405-020-
06267-2.
Le Bon, S.D., et al., 2020. Psychophysical Evaluation of Chemosensory Functions 5 Weeks
after Olfactory Loss Due to COVID-19: a Prospective Cohort Study on 72 Patients.
European Archives of Oto-Rhino-Laryngology. https://doi.org/10.1007/s00405-020-
06267-2.
Borsetto, D., et al., 2020. Self-reported alteration of sense of smell or taste in patients with
COVID-19: a systematic review and meta-analysis on 3563 patients. Rhinology 58,
430–436.
Boscolo-Rizzo, P., et al., 2020. Evolution of altered sense of smell or taste in patients with
mildly symptomatic COVID-19. JAMA Otolaryngology - Head and Neck Surgery 146,
1–5.
Bryche, B., et al., 2020. Massive transient damage of the olfactory epithelium associated
with infection of sustentacular cells by SARS-CoV-2 in golden Syrian hamsters. Brain
Behav. Immun. 89, 579–586.
Bulfamante, G., et al., 2020. First ultrastructural autoptic findings of sars-cov-2 in
olfactory pathways and brainstem. Minerva Anestesiol. 86, 678–679.
Cain, W.S., Rabin, M.D., 1989. Comparability of two tests of olfactory functioning. Chem.
Senses 14, 479–485.
Cain, W.S., Gent, J.F., Goodspeed, R., Leonard, G., 1988. Evaluation of olfactory
dysfunction in the Connecticut chemosensory clinical research center. Laryngoscope
98, 83–88.
Casez, O., et al., 2020. SARS-CoV-2 related encephalitis: MRI pattern of the olfactory tract
involvement. Neurology. https://doi.org/10.1212/wnl.0000000000011150,
10.1212/WNL.0000000000011150.
Castelli, M., et al., 2020. Prevalence and risk factors for lung involvement on low-dose
chest CT (LDCT) in a paucisymptomatic population of 247 patients affected by
COVID-19. Insight. Imag. 11.
Chachkhiani, D., et al., 2020. Neurological complications in a predominantly African
American sample of COVID-19 predict worse outcomes during hospitalization. Clin.
Neurol. Neurosurg. 197.
Chary, E., et al., 2020. Prevalence and recovery from olfactory and gustatory dysfunctions
in covid-19 infection: a prospective multicenter study. Am. J. Rhinol. Allergy 34,
686–693.
Chen, M., et al., 2020. Elevated ACE-2 expression in the olfactory neuroepithelium:
implications for anosmia and upper respiratory SARS-CoV-2 entry and replication.
Eur. Respir. J. 56.
Chetrit, A., et al., 2020. Magnetic resonance imaging of COVID-19 anosmic patients
reveals abnormalities of the olfactory bulb: preliminary prospective study. J. Infect.
81, 816–846.
Chi, H., et al., 2020. One-seventh of patients with covid-19 had olfactory and gustatory
abnormalities as their initial symptoms: a systematic review and meta-analysis. Life
10, 1–8.
Chiu, A., et al., 2020. COVID-19-induced anosmia associated with olfactory bulb atrophy.
Neuroradiology. https://doi.org/10.1007/s00234-020-02554-1.
Cocco, A., et al., 2020. Neurological features in SARS-CoV-2-infected patients with smell
and taste disorder. J. Neurol. https://doi.org/10.1007/s00415-020-10135-8.
Croy, I., Nordin, S., Hummel, T., 2014. Olfactory disorders and quality of life-an updated
review. Chem. Senses 39, 185–194.
Cruz, A.T., Zeichner, S.L., 2020. COVID-19 in children: initial characterization of the
pediatric disease. Pediatrics 145, 19–21.
COVID-19 Anosmia Reporting Tool. https://www.entnet.org/content/reporting-tool-pati
ents-anosmia-related-covid-19.
Dawson, P., et al., 2020. Loss of taste and smell as distinguishing symptoms of COVID-19.
Clin. Infect. Dis. https://doi.org/10.1101/2020.05.13.20101006.9
Dekkers, O.M., et al., 2019. COSMOS-E: guidance on conducting systematic reviews and
meta-analyses of observational studies of etiology. PLoS Med. 16.
Desiato, V.M., et al., 2020. The prevalence of olfactory dysfunction in the general
population: a systematic review and meta-analysis. Am. J. Rhinol. Allergy. https://
doi.org/10.1177/1945892420946254.
Dixon, B.E., et al., 2020. Symptoms and Symptom Clusters Associated with SARS-CoV-2
Infection in Community-Based Populations: Results from a Statewide Epidemiological
Study. medRxiv : the Preprint Server for Health Sciences. https://doi.org/10.1101/
2020.10.11.20210922.
Doty, R.L., Shaman, P., Kimmelman, C.P., Dann, M.S., 1984. University of Pennsylvania
smell identification test: a rapid quantitative olfactory function test for the clinic.
Laryngoscope 94, 176–178.
D'Ascanio, L., et al., 2020. Olfactory dysfunction in COVID-19 patients: prevalence and
prognosis for recovering sense of smell. Otolaryngol. Head Neck Surg. https://
doi.org/10.1177/0194599820943530. United States.
Ebell, M.H., Chupp, H., Cai, X., Bentivegna, M., Kearney, M., 2020. Accuracy of signs and
symptoms for the diagnosis of community-acquired pneumonia: a meta-analysis.
Acad. Emerg. Med. 27, 541–553.
Eliezer, M., et al., 2020. Loss of smell in COVID-19 patients: MRI data reveals a transient
edema of the olfactory clefts. Neurology. https://doi.org/10.1212/
wnl.0000000000010806, 10.1212/WNL.0000000000010806.
von Elm, E., et al., 2007. The Strengthening the Reporting of Observational Studies in
Epidemiology (STROBE) statement: guidelines for reporting observational studies.
Lancet 370, 1453–1457.
Fantozzi, P.J., et al., 2020. Xerostomia, gustatory and olfactory dysfunctions in patients
with COVID-19. American Journal of Otolaryngology - Head and Neck Medicine and
Surgery 41.
Favas, T.T., et al., 2020. Neurological manifestations of COVID-19: a systematic review
and meta-analysis of proportions. Neurol. Sci. 41, 3437–3470.
Foster, K.J., Jauregui, E., Tajudeen, B., Bishehsari, F., Mahdavinia, M., 2020. Smell loss is
a prognostic factor for lower severity of coronavirus disease 2019. Ann. Allergy
Asthma Immunol. 125, 481–483.
Ganz-Lord, F., Segal, K.R., Rinke, M. L. Title, 2020. Covid-19 symptoms, duration, and
prevalence among healthcare workers in the New York metropolitan area. Infect.
Control Hosp. Epidemiol. https://doi.org/10.1017/ice.2020.1334.
Garg, R., et al., 2020. Neurological symptoms as initial manifestation of Covid-19-An
observational study. Ann. Indian Acad. Neurol. 23, 482–486.
Gelardi, M., Trecca, E., Cassano, M., Ciprandi, G., 2020. Smell and taste dysfunction
during the covid-19 outbreak: a preliminary report. Acta Biomed. 91, 230–231.
Gerkin, R.C., et al., 2020. Recent smell loss is the best predictor of COVID-19: a
preregistered, cross-sectional study. medRxiv. https://doi.org/10.1101/
2020.07.22.20157263, 2020.07.22.20157263.
Giorli, A., et al., 2020. A literature systematic review with meta-analysis of symptoms
prevalence in covid-19: the relevance of olfactory symptoms in infection not
requiring hospitalization. Curr. Treat. Options Neurol. 22.
GLOBAL CONSORTIUM FOR CHEMOSENSORY RESEARCH. https://gcchemosensr.org/
projects/.
G€ozen, E.D., et al., 2020. Evaluation of olfactory function with objective tests in COVID-
19-positive patients: a cross-sectional study. Ear Nose Throat J. https://doi.org/
10.1177/0145561320975510.
Gupta, A., et al., 2020. Extrapulmonary manifestations of COVID-19. Nat. Med. 26,
1017–1032.
Hajikhani, B., et al., 2020. Olfactory and gustatory dysfunction in COVID-19 patients: a
meta-analysis study. Physiol. Rep. 8.
Hannum, M.E., et al., 2020. Objective sensory testing methods reveal a higher prevalence
of olfactory loss in COVID-19–positive patients compared to subjective methods: a
systematic review and meta-analysis. Chem. Senses. https://doi.org/10.1093/
chemse/bjaa064.
Hauchecorne, M., Baldini, C., Foulon, S., Bayle, A., Albiges, L., 2020. Outcome of older
cancer patients infected with COVID-19 at gustave roussy cancer center. ESMO
Virtual Congress. https://doi.org/10.1016/annonc/annonc289.
Hintschich, C.A., et al., 2020. Psychophysical tests reveal impaired olfaction but
preserved gustation in COVID-19 patients. Int. For. Allergy Rhinol. 10, 1105–1107.
Hoffman, H.J., Rawal, S., Li, C.M., Duffy, V.B., 2016. New chemosensory component in
the U.S. National Health and Nutrition Examination Survey (NHANES): first-year
results for measured olfactory dysfunction. Rev. Endocr. Metab. Disord. 17, 221–240.
Hopkins, C., Gillett, S., Slack, R., Lund, V.J., Browne, J.P., 2009. Psychometric validity of
the 22-item sinonasal outcome test. Clin. Otolaryngol. 34, 447–454.
Houlihan, C.F., Beale, R., 2020. The complexities of SARS-CoV-2 serology. Lancet Infect.
Dis. https://doi.org/10.1016/S1473-3099(20)30699-X.
Hummel, T., Sekinger, B., Wolf, S.R., Pauli, E., Kobal, G., 1997. ‘Sniffin’ sticks'. Olfactory
performance assessed by the combined testing of odor identification, odor
discrimination and olfactory threshold. Chem. Senses 22, 39–52.
Iannuzzi, L., et al., 2020. Gaining back what is lost: recovering the sense of smell in mild
to moderate patients after COVID-19. Chem. Senses. https://doi.org/10.1093/
chemse/bjaa066.
Ibekwe, T.S., Fasunla, A.J., Orimadegun, A.E., 2020. Systematic review and meta-analysis
of smell and taste disorders in COVID-19. OTO Open 4, 2473974X2095797.
WHO Director- General's Opening Remarks at the Media Briefing on COVID-19 - 11
March 2020 11, 2020. World Health Organization.
Izquierdo-Domínguez, A., et al., 2020. Smell and taste dysfunction in covid-19 is
associated with younger age in ambulatory settings: a multicenter cross-sectional
study. J. Invest. Allergol. Clin. Immunol. 30, 346–357.
Jin, X., et al., 2020. Epidemiological, clinical and virological characteristics of 74 cases of
coronavirus-infected disease 2019 (COVID-19) with gastrointestinal symptoms. Gut.
https://doi.org/10.1136/gutjnl-2020-320926.
A. Boscutti et al. Brain, Behavior, & Immunity - Health 15 (2021) 100268Joffily, L., et al., 2020. The close relationship between sudden loss of smell and COVID-
19. Braz. J. Otorhinolaryngol. 86, 632–638.
John Hopkins Coronavirus Resource Center. COVID-19 Dashboard by the Center for
Systems Science and Engineering (CSSE) at Johns Hopkins University (JHU). https://
coronavirus.jhu.edu/map.html.
Just, J., Puth, M.T., Regenold, F., Weckbecker, K., Bleckwenn, M., 2020. Risk factors for a
positive SARS-CoV-2 PCR in patients with common cold symptoms in a primary care
setting – a retrospective analysis based on a joint documentation standard. BMC Fam.
Pract. 21.
Kandemirli, S.G., Altundag, A., Yildirim, D., Tekcan Sanli, D.E., Saatci, O., 2020. Olfactory
Bulb MRI and Paranasal Sinus CT Findings in Persistent COVID-19 Anosmia.
Academic Radiology. https://doi.org/10.1016/j.acra.2020.10.006.
Kempker, R.R., et al., 2020. Loss of Smell and Taste Among Healthcare Personnel
Screened for Coronavirus 2019. Clinical Infectious Diseases. https://doi.org/
10.1093/cid/ciaa877.
Kirschenbaum, D., et al., 2020. Inflammatory olfactory neuropathy in two patients with
COVID-19. Lancet 396, 166.
Klopfenstein, T., et al., 2020. New loss of smell and taste: uncommon symptoms in
COVID-19 patients in Nord Franche-Comte cluster, France. Int. J. Infect. Dis. 100,
117–122.
Komagamine, J., Yabuki, T., 2020. Initial symptoms of patients with coronavirus disease
2019 in Japan: a descriptive study. J. General Family Med. https://doi.org/10.1002/
jgf2.378.
Landis, B.N., et al., 2009. ‘taste Strips’ - a rapid, lateralized, gustatory bedside
identification test based on impregnated filter papers. J. Neurol. 256, 242–248.
Laurendon, T., et al., 2020. Bilateral transient olfactory bulb edema during COVID-19-
related anosmia. Neurology 95, 224–225.
Lechien, J.R., et al., 2020. Loss of smell and taste in 2013 European patients with mild to
moderate COVID-19. Ann. Intern. Med. 173, 672–675.
Lechien, J.R., et al., 2020. Olfactory and gustatory dysfunctions as a clinical presentation
of mild-to-moderate forms of the coronavirus disease (COVID-19): a multicenter
European study. Eur. Arch. Oto-Rhino-Laryngol. 277, 2251–2261.
Lechien, J.R., et al., 2020. Psychophysical olfactory tests and detection of COVID-19 in
patients with sudden onset olfactory dysfunction: a prospective study. Ear Nose
Throat J. 99, 579–583.
Lechien, J.R., et al., 2020. Olfactory and gustatory dysfunctions as a clinical presentation
of mild-to-moderate forms of the coronavirus disease (COVID-19): a multicenter
European study. Eur. Arch. Oto-Rhino-Laryngol. https://doi.org/10.1007/s00405-
020-05965-1.
Lee, Y., Min, P., Lee, S., Kim, S.W., 2020. Prevalence and duration of acute loss of smell or
taste in COVID-19 patients. J. Kor. Med. Sci. 35, 1–6.
Li, J., et al., 2020. Olfactory dysfunction in recovered coronavirus disease 2019 (COVID-
19) patients. Mov. Disord. 35, 1100–1101.
Li, C.W., et al., 2020. Anosmia and olfactory tract neuropathy in a case of COVID-19.
J. Microbiol. Immunol. Infect. https://doi.org/10.1016/j.jmii.2020.05.017.
Liang, Y.C., Tsai, Y.S., Syue, L.S., Lee, N.Y., Li, C.W., 2020. Olfactory bulb atrophy in a
case of COVID-19 with hyposmia. Acad. Radiol. 27, 1649–1650.
Liberati, A., et al., 2009. The PRISMA statement for reporting systematic reviews and
meta-analyses of studies that evaluate health care interventions: explanation and
elaboration. PLoS Med. 6.
Lima, M.A., et al., 2020. Smell dysfunction in COVID-19 patients: more than a yes-no
question. J. Neurol. Sci. 418.
Liu, G., Zong, G., Doty, R.L., Sun, Q., 2016. Prevalence and risk factors of taste and smell
impairment in a nationwide representative sample of the US population: a cross-
sectional study. BMJ Open 6.
Lv, H., et al., 2020. Prevalence and recovery time of olfactory and gustatory dysfunction
in hospitalized patients with COVID-19 in Wuhan, China. Int. J. Infect. Dis. 100,
507–512.
Magnavita, N., Tripepi, G., Di Prinzio, R.R., 2020. Symptoms in health care workers
during the covid-19 epidemic. A cross-sectional survey. Int. J. Environ. Res. Publ.
Health 17, 1–15.
Makda, A., Kumar, S., Kumar, A., Kumar, V., Rizwan, A., 2020. The frequency of
neurological symptoms in COVID-19 patients at a tertiary care hospital in Pakistan.
Cureus. https://doi.org/10.7759/cureus.10360.
Mao, L., et al., 2020. Neurologic manifestations of hospitalized patients with coronavirus
disease 2019 in Wuhan, China. JAMA Neurology. https://doi.org/10.1001/
jamaneurol.2020.1127.
Mao, L., et al., 2020. Neurologic manifestations of hospitalized patients with coronavirus
disease 2019 in Wuhan, China. JAMA Neurology 77, 683–690.
Mari~no-Sanchez, F., Santamaría-Gadea, A., de los Santos, G., Alobid, I., Mullol, J., 2020.
Psychophysical olfactory testing in COVID-19: is smell function really impaired in
nearly all patients? Int. For. Allergy Rhinol. 10, 951–952.
Massarelli, O., et al., 2018. Sensory recovery of myomucosal flap oral cavity
reconstructions. Head Neck 40, 467–474.
Matschke, J., et al., 2020. Neuropathology of patients with COVID-19 in Germany: a post-
mortem case series. Lancet Neurol. 19, 919–929.
Meinhardt, J., et al., 2020. Olfactory Transmucosal SARS-CoV-2 Invasion as Port of
Central Nervous System Entry in COVID-19 Patients. https://doi.org/10.1101/
2020.06.04.135012.
Meini, S., Suardi, L.R., Busoni, M., Roberts, A.T., Fortini, A., 2020. Olfactory and
Gustatory Dysfunctions in 100 Patients Hospitalized for Covid-19: Sex Differences
and Recovery Time in Real-Life. https://doi.org/10.21203/rs.3.rs-28881/v1.
De Melo, G.D., et al., 2020. COVID-19-associated olfactory dysfunction reveals SARS-CoV-
2 neuroinvasion and persistence in the olfactory system. bioRxiv 4,
2020.11.18.388819.10Menni, C., et al., 2020. Loss of smell and taste in combination with other symptoms is a
strong predictor of COVID-19 infection. medRxiv. https://doi.org/10.1101/
2020.04.05.20048421, 2020.04.05.20048421.
Mercante, G., et al., 2020. Prevalence of taste and smell dysfunction in coronavirus
disease 2019. JAMA Otolaryngology - Head and Neck Surgery 146, 723–728.
Merkely, B, et al., 2020. Novel Coronavirus Epidemic in the Hungarian Population, a
Cross-Sectional Nationwide Survey to Support the Exit Policy in Hungary, 4th ed. 42.
GeroScience, pp. 1063–1074.
Mishra, P., Gowda, V., Dixit, S., Kaushik, M., 2020. Prevalence of new onset anosmia in
COVID-19 patients: is the trend different between European and Indian population?
Indian J.Otolaryngol. Head Neck Surg. 72, 484–487.
Moein, S.T., et al., 2020. Smell dysfunction: a biomarker for COVID-19. Int. For. Allergy
Rhinol. 10, 944–950.
Moein, S.T., Hashemian, S.M.R., Tabarsi, P., Doty, R.L., 2020. Prevalence and reversibility
of smell dysfunction measured psychophysically in a cohort of COVID-19 patients.
Int. For. Allergy Rhinol. 10, 1127–1135.
Moein, S.T., et al., 2020. Smell dysfunction: a biomarker for COVID-19. Int. For. Allergy
Rhinol. https://doi.org/10.1002/alr.22587.
Morbini, P., et al., 2020. Ultrastructural evidence of direct viral damage to the olfactory
complex in patients testing positive for SARS-COV-2. JAMA Otolaryngology - Head
and Neck Surgery 146, 972–973.
Naeini, A.S., et al., 2020. Paranasal sinuses computed tomography findings in anosmia of
COVID-19. American Journal of Otolaryngology - Head and Neck Medicine and
Surgery 41.
Ninchritz-Becerra, E., et al., 2020. Subjective evaluation of smell and taste dysfunction in
patients with mild COVID-19 in Spain. Med. Clínica. https://doi.org/10.1016/
j.medcli.2020.08.004.
Nouchi, A., et al., 2020. Prevalence of hyposmia and hypogeusia in 390 COVID-19
hospitalized patients and outpatients: a cross-sectional study. Eur. J. Clin. Microbiol.
Infect. Dis. https://doi.org/10.1007/s10096-020-04056-7.
Orrù, G., et al., 2020. Neurological complications of covid-19 and possible neuroinvasion
pathways: a systematic review. Int. J. Environ. Res. Publ. Health 17, 1–18.
Otte, M.S., Eckel, H.N.C., Poluschkin, L., Klussmann, J.P., Luers, J.C., 2020. Olfactory
dysfunction in patients after recovering from COVID-19. Acta Otolaryngol. https://
doi.org/10.1080/00016489.2020.1811999.
€Ozçelik Korkmaz, M., Egilmez, O.K., €Ozçelik, M.A., Güven, M., 2020. Otolaryngological
Manifestations of Hospitalised Patients with Confirmed COVID-19 Infection.
European Archives of Oto-Rhino-Laryngology. https://doi.org/10.1007/s00405-020-
06396-8.
Paderno, A., et al., 2020. Olfactory and Gustatory Outcomes in COVID-19: A Prospective
Evaluation in Nonhospitalized Subjects. Otolaryngology - Head and Neck Surgery,
United States. https://doi.org/10.1177/0194599820939538.
Pang, K.W., Chee, J., Subramaniam, S., Ng, C.L., 2020. Frequency and clinical utility of
olfactory dysfunction in COVID-19: a systematic review and meta-analysis. Curr.
Allergy Asthma Rep. 20.
Parma, V., et al., 2020. More than smell-COVID-19 is associated with severe impairment
of smell, taste, and chemesthesis. Chem. Senses 45, 609–622.
Parma, V., et al., 2020. More than Just Smell - COVID-19 Is Associated with Severe
Impairment of Smell, Taste, and Chemesthesis medRxiv.
Petersen, M.S., et al., 2020. Long COVID in the Faroe Islands - a longitudinal study among
non-hospitalized patients. Clin. Infect. Dis. https://doi.org/10.1093/cid/ciaa1792.
Petrocelli, M., et al., 2020. Remote psychophysical evaluation of olfactory and gustatory
functions in early-stage coronavirus disease 2019 patients: the Bologna experience of
300 cases. J. Laryngol. Otol. 134, 571–576.
Pinato, D.J., et al., 2020. Presenting features and early mortality from SARS-CoV-2
infection in cancer patients during the initial stage of the COVID-19 pandemic in
Europe. Cancers 12, 1–13.
Politi, L.S., Salsano, E., Grimaldi, M., 2020. Magnetic resonance imaging alteration of the
brain in a patient with coronavirus disease 2019 (COVID-19) and anosmia. JAMA
Neurology 77, 1028–1029.
Putman, M.S., Ruderman, E.M., Niforatos, J.D., 2020. Publication rate and journal review
time of COVID-19–related research. Mayo Clin. Proc. 95, 2290–2291.
Rabin, R.C., 2020. Lost Sense of Smell May Be Peculiar Clue to Coronavirus Infection. The
New York Times.
Radke, E.G., et al., 2019. Development of outcome-specific criteria for study evaluation in
systematic reviews of epidemiology studies. Environ. Int. 130.
Ramasamy, K., Saniasiaya, J., Abdul Gani, N., 2020. Olfactory and gustatory dysfunctions
as a clinical manifestation of coronavirus disease 2019 in a Malaysian tertiary center.
Ann. Otol. Rhinol. Laryngol. https://doi.org/10.1177/0003489420963165.
Recalcati, S., 2020. Cutaneous manifestations in COVID-19: a first perspective. J. Eur.
Acad. Dermatol. Venereol. 34, e212–e213.
Rocke, J., Hopkins, C., Philpott, C., Kumar, N., 2020. Is loss of sense of smell a diagnostic
marker in COVID-19: a systematic review and meta-analysis. Clin. Otolaryngol. 45,
914–922.
Rodriguez, S., et al., 2020. Innate Immune Signaling in the Olfactory Epithelium Reduces
Odorant Receptor Levels: Modeling Transient Smell Loss in COVID-19 Patients.
medRxiv : the Preprint Server for Health Sciences. https://doi.org/10.1101/
2020.06.14.20131128.
Rogers, J.P., et al., 2020. Psychiatric and neuropsychiatric presentations associated with
severe coronavirus infections: a systematic review and meta-analysis with
comparison to the COVID-19 pandemic. Lancet Psychiatr. 7, 611–627.
Roland, L.T., Gurrola, J.G., Loftus, P.A., Cheung, S.W., Chang, J.L., 2020. Smell and taste
symptom-based predictive model for COVID-19 diagnosis. Int. For. Allergy Rhinol.
10, 832–838.
Romero-Sanchez, C.M., et al., 2020. Neurologic manifestations in hospitalized patients
with COVID-19: the ALBACOVID registry. Neurology 95, e1060–e1070.
A. Boscutti et al. Brain, Behavior, & Immunity - Health 15 (2021) 100268Romero-Gameros, C.A., et al., 2020. Evaluation of predictive value of olfactory
dysfunction, as a screening tool for COVID -19. Laryngoscope Invest. Otolaryngol.
https://doi.org/10.1002/lio2.482.
Rubio-Rivas, M., et al., 2020. Predicting clinical outcome with phenotypic clusters in
COVID-19 pneumonia: an analysis of 12,066 hospitalized patients from the Spanish
registry SEMI-COVID-19. J. Clin. Med. 9, 3488.
Salepci, E., et al., 2020. Symptomatology of COVID-19 from the otorhinolaryngology
perspective: a survey of 223 SARS-CoV-2 RNA-positive patients. Eur. Arch. Oto-
Rhino-Laryngol. https://doi.org/10.1007/s00405-020-06284-1.
Samimi Ardestani, S.H., et al., 2020. The coronavirus disease 2019: the prevalence,
prognosis, and recovery from olfactory dysfunction (OD). Acta Otolaryngol. https://
doi.org/10.1080/00016489.2020.1836397.
Saniaslaya, J., Islam, A., Abdullah, B., 2020. Prevalence of olfactory dysfunction in
coronavirus disease 2019 (COVID-19): a meta-analysis of 27492 patients.
Laryngoscope 131 (4), 865–878. https://doi.org/10.1002/lary.29286.
Sanli, D.E.T., et al., 2021. Relationship between disease severity and serum IL-6 levels in
COVID-19 anosmia. American Journal of Otolaryngology - Head and Neck Medicine
and Surgery 42.
Sayin, _I, 2020. Taste and smell impairment in COVID-19: an AAO-HNS anosmia reporting
tool-based comparative study. Otolaryngol Head Neck Surg. 163 (3), 473–479,
United States. https://doi.org/10.1177/0194599820931820.
Schurink, B., et al., 2020. Viral presence and immunopathology in patients with lethal
COVID-19: a prospective autopsy cohort study. Lancet Microbe 1, e290–e299.
Seok, J., Shim, Y.J., Rhee, C.S., Kim, J.W., 2017. Correlation between olfactory severity
ratings based on olfactory function test scores and self-reported severity rating of
olfactory loss. Acta Otolaryngol. 137, 750–754.
Sheng, W.H., Liu, W. Da, Wang, J.T., Chang, S.Y., Chang, S.C., 2020. Dysosmia and
dysgeusia in patients with COVID-19 in northern Taiwan. J. Formos. Med. Assoc.
https://doi.org/10.1016/j.jfma.2020.10.003.
Shor, N., Chougar, L., Pyatigorskaya, N., 2020. MR imaging of the olfactory bulbs in
patients with COVID-19 and anosmia: how to avoid misinterpretation. Am. J.
Neuroradiol. https://doi.org/10.3174/ajnr.a6921.
Siso-Almirall, A., et al., 2020. Prognostic factors in Spanish COVID-19 patients: a case
series from Barcelona. PloS One 15.
Soter, A., et al., 2008. Accuracy of self-report in detecting taste dysfunction. Laryngoscope
118, 611–617.
Spoldi, C., et al., 2020. Isolated olfactory cleft involvement in SARS-CoV-2 infection:
prevalence and clinical correlates. Eur. Arch. Oto-Rhino-Laryngol. https://doi.org/
10.1007/s00405-020-06165-7.
Stavem, K., Ghanima, W., Olsen, M.K., Gilboe, H.M., Einvik, G., 2020. Persistent
symptoms 1.5-6 months after COVID-19 in non-hospitalised subjects: a population-
based cohort study. Thorax. https://doi.org/10.1136/thoraxjnl-2020-216377.
Strauss, S.B., Lantos, J.E., Heier, L.A., Shatzkes, D.R., Phillips, C.D., 2020. Olfactory bulb
signal abnormality in patients with COVID-19 who present with neurologic
symptoms. Am. J. Neuroradiol. 41, 1882–1887.
Sun, S.H., et al., 2020. A mouse model of SARS-CoV-2 infection and pathogenesis. Cell
Host Microbe 28, 124–133 e4.
Suratannon, N., Dik, W.A., Chatchatee, P., Hagen, P. M. van, 2020. COVID-19 in children:
heterogeneity within the disease and hypothetical pathogenesis. Asian Pac. J. Allergy
Immunol. 38, 170–177.
Therchilsen, J.H., et al., 2020. Self-collected versus healthcare Worker-collected swabs in
the diagnosis of severe acute respiratory syndrome coronavirus 2. Diagnostics 10.
Thu, S.S., Matin, N., Levine, S.R., 2020. Olfactory gyrus intracerebral hemorrhage in a
patient with COVID-19 infection. J. Clin. Neurosci. 79, 275–276.
Tong, J.Y., Wong, A., Zhu, D., Fastenberg, J.H., Tham, T., 2020. The prevalence of
olfactory and gustatory dysfunction in COVID-19 patients: a systematic review and
meta-analysis. Otolaryngol. Head Neck Surg. 163, 3–11.11Torabi, A., et al., 2020. Proinflammatory cytokines in the olfactory mucosa result in
COVID-19 induced anosmia. ACS Chem. Neurosci. 11, 1909–1913.
Tostmann, A., et al., 2020. Strong associations and moderate predictive value of early
symptoms for SARS-CoV-2 test positivity among healthcare workers, The
Netherlands, March 2020. Euro Surveill. 25.
Tsivgoulis, G., et al., 2020. Olfactory bulb and mucosa abnormalities in persistent COVID-
19-induced anosmia: a magnetic resonance imaging study. Eur. J. Neurol. https://
doi.org/10.1111/ene.14537.
Tudrej, B., et al., 2020. Self-reported Loss of Smell and Taste in SARS-CoV-2 Patients:
Primary Care Data to Guide Future Early Detection Strategies. https://doi.org/
10.21203/rs.3.rs-28701/v1.
Uygun, €O., et al., 2020. Headache characteristics in COVID-19 pandemic-a survey study.
J. Headache Pain 21.
Vaira, L.A., et al., 2020. Gustatory dysfunction: a highly specific and smell-independent
symptom of COVID-19. Indian J.Otolaryngol. Head Neck Surg. https://doi.org/
10.1007/s12070-020-02182-4.
Vaira, L.A., et al., 2020. Olfactory and gustatory function impairment in COVID-19
patients: Italian objective multicenter-study. Head Neck 42, 1560–1569.
Vaira, L.A., et al., 2020. Do olfactory and gustatory psychophysical scores have prognostic
value in COVID-19 patients? A prospective study of 106 patients. J. Otolaryngol.
Head Neck Surg. 49.
Vaira, L.A., et al., 2020. Smell and taste recovery in coronavirus disease 2019 patients: a
60-day objective and prospective study. J. Laryngol. Otol. 134, 703–709.
Vaira, L.A., et al., 2020. Validation of a self-administered olfactory and gustatory test for
the remotely evaluation of COVID-19 patients in home quarantine. Head Neck 42,
1570–1576.
Vaira, L.A., et al., 2020. Olfactory epithelium histopathological findings in long-term
coronavirus disease 2019 related anosmia. J. Laryngol. Otol. https://doi.org/
10.1017/S0022215120002455.
Vena, A., et al., 2020. Prevalence of antibodies to SARS-CoV-2 in Italian adults and
associated risk factors. J. Clin. Med. 9, 2780.
Venugopal, U., et al., 2021. SARS-CoV-2 seroprevalence among health care workers in a
New York City hospital: a cross-sectional analysis during the COVID-19 pandemic.
Int. J. Infect. Dis. 102, 63–69.
Vogalis, F., Hegg, C.C., Lucero, M.T., 2005. Ionic conductances in sustentacular cells of
the mouse olfactory epithelium. J. Physiol. 562, 785–799.
Waterfield, T., et al., 2020. Seroprevalence of SARS-CoV-2 antibodies in children: a
prospective multicentre cohort study. Arch. Dis. Child. https://doi.org/10.1136/
archdischild-2020-320558.
Wu, C., et al., 2020. Risk factors associated with acute respiratory distress syndrome and
death in patients with coronavirus disease 2019 pneumonia in Wuhan, China. JAMA
Int. Med. 180, 934–943.
Yan, C.H., Faraji, F., Prajapati, D.P., Ostrander, B.T., DeConde, A.S., 2020. Self-reported
olfactory loss associates with outpatient clinical course in Covid-19. Int. For. Allergy
Rhinol. https://doi.org/10.1111/alr.22592.
Yan, C.H., Faraji, F., Prajapati, D.P., Boone, C.E., DeConde, A.S., 2020. Association of
chemosensory dysfunction and COVID-19 in patients presenting with influenza-like
symptoms. Int. For. Allergy Rhinol. 10, 806–813.
Yan, C.H., Faraji, F., Prajapati, D.P., Ostrander, B.T., DeConde, A.S., 2020. Self-reported
olfactory loss associates with outpatient clinical course in COVID-19. Int. For. Allergy
Rhinol. 10, 821–831.
Zhang, A.J., et al., 2020. Severe acute respiratory syndrome coronavirus 2 infects and
damages the mature and immature olfactory sensory neurons of hamsters. Clin.
Infect. Dis. https://doi.org/10.1093/cid/ciaa995.
Zheng, Y.Y., Ma, Y.T., Zhang, J.Y., Xie, X., 2020. COVID-19 and the cardiovascular
system. Nat. Rev. Cardiol. 17, 259–260.
Zheng, J., et al., 2020. COVID-19 treatments and pathogenesis including anosmia in K18-
hACE2 mice. Nature. https://doi.org/10.1038/s41586-020-2943-z.
